Weekly results update
Last update: 28/08/2020 | Total Count: 8761 | Reported by PwMS: 7170 | Reported by health care professionals (HCP): 1591
|Fast Data Entry Track
Entries directly into the QMENTA platform. Learn more here.
COVID19 datasets from participating registries and cohorts collecting information directly from PwMS. Learn more here.
COVID19 core datasets from participating registries and cohorts collecting information via HCP. Learn more here.
|Total number: 1375||Total number: 5795||Total number: 1591|
|reported by PwMS: 1251||reported by PwMS: 5795|
|reported by HCP: 124||reported by HCP: 1591|
|with (suspected) COVID19: 356||with (suspected) COVID19: 390||with (suspected) COVID19: 1282|
|with confirmed lab test: 87||with confirmed lab test: 53||with confirmed lab test: 883|
|different countries: 67||different countries: 82||different countries: 24|
|Type of MS||Type of MS||Type of MS|
|CIS 19 - RRMS 1053 - PPMS 78 - SPMS 91||CIS 53 - RRMS 3958 - PPMS 538 - SPMS 956||CIS 18- RRMS 1220 - PPMS 75 - SPMS 231|
|not sure: 134||not sure: 277||not sure: 25|
|Not currently treated: 117||Not currently treated: 784||Not currently treated: 40|
|Alemtuzumab: 38||Alemtuzumab: 49||Alemtuzumab: 13|
|Cladribine: 49||Cladribine: 106||Cladribine: 20|
|Dimethyl fumarate: 227||Dimethyl fumarate: 180||Dimethyl fumarate: 128|
|Fingolimod: 180||Fingolimod: 535||Fingolimod: 108|
|Glatimarer: 105||Glatimarer: 188||Glatimarer: 62|
|Interferon: 186||Interferon: 171||Interferon: 121|
|Natalizumab: 102||Natalizumab: 318||Natalizumab: 91|
|Ocrelizumab: 136||Ocrelizumab: 499||Ocrelizumab: 131|
|Rituximab: 37||Rituximab: 70||Rituximab: 139|
|Siponimod: 0||Siponimod: 13||Siponimod: 4|
|Teriflunomide: 106||Teriflunomide: 204||Teriflunomide: 70|
|Currently on another drug: 214||Currently on another drug: 79||Currently on another drug: 4|
For general enquiries, please contact us by using the form below
Fill in and submit the form to the left
Once we receive your information, one of our team members will follow up with you shortly.
We'll discuss how we can contribute to the MS Global Data-Sharing Initiative